Abbreviations
ACQ-6 | = | Asthma Control Questionnaire |
AAER | = | Annualized Asthma Exacerbation Rate |
Arachidonic acid 15-lipoxygenase | = | ALOX15, 15-lipoxygenase |
ATP | = | adenosine triphosphate |
CD | = | Cluster of differentiation |
CRS | = | Chronic Rhinosinusitis |
CRSwNP | = | Chronic Rhinosinusitis with nasal polyps |
CRSsNP | = | Chronic Rhinosinusitis without nasal polyps |
DC | = | dendritic cells |
FeNO | = | Fractional exhaled nitric oxide |
MC | = | mast cells |
IgE | = | immunoglobulin |
ILC | = | innate lymphoid cell |
IL | = | interleukin |
IL-R | = | interleukin-receptor |
mAb | = | monoclonal antibodies |
Nitric oxide synthase | = | NOS |
NP | = | nasal polyp |
RORα | = | RAR-related orphan receptor alpha. |
T2 | = | Type 2 |
TSLP | = | thymic stromal lymphopoietin |
TSPLR | = | TSLP receptor |
Declaration of interest
A Bourdin reports grants, personal fees, non-financial support, and/or other from AstraZeneca and Boehringer Ingelheim; Astra Zeneca, GSK, Novartis, Sanofi Regeneron, Boehringer Ingelheim and Chiesi. C Jeremy reports funding’s by GlaxoSmithKline, Astra Zeneca, Sanofi. L Crampette reports speaker fees, non-financial support and/other from Medtronic, Novartis, Zambon, ALK, AstraZeneca, Sanofi Genzyme. A Engi reports personal fees, non-financial support from Sanofi, Astra Zeneca The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Reviewer disclosures
Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.